Gyrolab Resources

Find technical documentation on our products as well as scientific references. 

Mark Dysinger GLP-1 quantitation: Gyros vs. other detection platforms
Recorded Seminar: Mark Dysinger, Senior Scientist, Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, presents ‘Glucagon-Like Peptide 1 Quantitation: Gyros vs Other Detection Platforms'. 
[Seminar]

Diane Hamlin on the performance of Gyrolab xP workstation
Recorded Seminar: Diane Hamlin, Eli Lilly and Company, presents 'Performance of the Gyrolab xP System for Custom Development of Preclinical Urinary Renal Biomarker Assays'. 
[Seminar]

Sabrina Lory Developing fit-for-purpose immunoassays
Recorded Seminar: Sabrina Lory, Head of the Bioanalytical Assay Laboratory, NovImmune, presents ‘Developing fit for purpose assays using the Gyrolab platform'. 
[Seminar]

Jun Heo on using Gyrolab xP to automate high throughput HCP analysis
Recorded Seminar: Jun Heo, Analytical Biochemist, Biologics-New and Enabling Technologies (BNET), Merck & Co., Inc., presents 'The Automation of a High Throughput Residual Assay to Support In-Process Analysis of Monoclonal Antibodies'. 
[Seminar]

Daniel Schiwek on The value of Gyrolab xP workstation in HCP analysis and bioprocess
Recorded Seminar: Daniel Schiwek, Project Evaluation Manager at Global Biological Operations, Lonza AG, Visp, Switzerland, presents ‘Biopharmaceutical manufacturing in microbial systems – Gyrolab as an analytical platform supporting process development'. 
[Seminar]

Shawn Fernando PK assays: Gyrolab helps to meet tight deadlines
Recorded Seminar: Shawn Fernando,  Senior Researcher, Bioanalytical Development, Morphotek, Exton, PA, USA, presents ‘Development and Validation of a Pharmacokinetic Assay on the Gyrolab Platform for Use in Phase II/III Clinical Trials'. 
[Seminar]

Annette Wu shows how Gyrolab xP workstation speeds up ADC assay development and throughput
Recorded Seminar: Annette Wu in the PDM group at Pfizer, La Jolla, CA, USA, presents ‘Case study: Antibody-drug conjugates TK study on Gyros' immunoassay platform'. 
[Seminar]